Desvenlafaxine Succinate
These highlights do not include all the information needed to use DESVENLAFAXINE SUCCINATE safely and effectively. See full prescribing information for DESVENLAFAXINE SUCCINATE. Desvenlafaxine Succinate Extended-Release Tablets, for oral use Initial U.S. Approval: 2008
7195b977-6c91-4fed-837d-9b146f051ce8
HUMAN PRESCRIPTION DRUG LABEL
Sep 12, 2023
Greenstone LLC
DUNS: 825560733
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
desvenlafaxine succinate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (10)
desvenlafaxine succinate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (10)
desvenlafaxine succinate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (10)
Drug Labeling Information
DRUG INTERACTIONS SECTION
7 DRUG INTERACTIONS
7.1 Drugs Having Clinically Important Interactions with Desvenlafaxine
Table 7: Clinically Important Drug Interactions with Desvenlafaxine
Monoamine Oxidase Inhibitors (MAOI) | |
Clinical Impact |
The concomitant use of SSRIs and SNRIs including desvenlafaxine with MAOIs increases the risk of serotonin syndrome. |
Intervention |
Concomitant use of desvenlafaxine is contraindicated: •
•
•
[see Dosage and Administration (2.7), Contraindications (4) and Warnings and Precautions (5.2)]. |
Examples |
selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue |
Other Serotonergic Drugs | |
Clinical Impact |
Concomitant use of desvenlafaxine with other serotonergic drugs increases the risk of serotonin syndrome. |
Intervention |
Monitor for symptoms of serotonin syndrome when desvenlafaxine is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of desvenlafaxine and/or concomitant serotonergic drugs [see Warnings and Precautions (5.2)]. |
Examples |
other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort |
Drugs that Interfere with Hemostasis | |
Clinical Impact |
Concomitant use of desvenlafaxine with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding. This may be due to the effect of desvenlafaxine on the release of serotonin by platelets. |
Intervention |
Closely monitor for bleeding for patients receiving an antiplatelet or anticoagulant drug when Desvenlafaxine is initiated or discontinued [see Warnings and Precautions (5.4)]. |
Examples |
NSAIDs, aspirin, and warfarin |
Drugs that are Primarily Metabolized by CYP2D6 | |
Clinical Impact |
Concomitant use of desvenlafaxine increases Cmax and AUC of a drug primarily metabolized by CYP2D6 which may increase the risk of toxicity of the CYP2D6 substrate drug [see Clinical Pharmacology (12.3)]. |
Intervention |
Original dose should be taken when co-administered with desvenlafaxine 100 mg or lower. Reduce the dose of these drugs by up to one-half if co-administered with 400 mg of desvenlafaxine. |
Examples |
desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine |
7.2 Drugs Having No Clinically Important Interactions with Desvenlafaxine
Based on pharmacokinetic studies, no dosage adjustment is required for drugs that are mainly metabolized by CYP3A4 (e.g., midazolam), or for drugs that are metabolized by both CYP2D6 and CYP3A4 (e.g., tamoxifen, aripiprazole), when administered concomitantly with desvenlafaxine [see Clinical Pharmacology (12.3)].
7.3 Alcohol
A clinical study has shown that desvenlafaxine does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking desvenlafaxine.
7.4 Drug-Laboratory Test Interactions
False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of desvenlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.
SPL UNCLASSIFIED SECTION
LAB-0780-8.0
SPL MEDGUIDE SECTION
MEDICATION GUIDE | |||
---|---|---|---|
What is the most important information I should know about desvenlafaxine? Desvenlafaxine can cause serious side effects, including: •
•
How can I watch for and try to prevent suicidal thoughts and actions? o
o
o
| |||
•
•
•
•
•
•
|
•
•
•
•
•
•
| ||
What is desvenlafaxine? •
| |||
Do not take desvenlafaxine if you: •
•
•
•
Do not start taking an MAOI for at least 7 days after you stop treatment with desvenlafaxine. | |||
Before taking desvenlafaxine tell your healthcare provider about all your medical conditions, including if you: •
•
•
•
•
•
•
•
•
•
•
o
o
•
Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal
supplements. | |||
•
•
•
•
•
•
•
•
•
•
•
•
•
| |||
Ask your healthcare provider if you are not sure if you are taking any of
these medicines. Your healthcare provider can tell you if it is safe to take
desvenlafaxine with your other medicines. | |||
How should I take desvenlafaxine? •
•
•
•
•
•
| |||
What should I avoid while taking desvenlafaxine? •
•
| |||
What are the possible side effects of desvenlafaxine?
1.
2.
| |||
•
•
•
•
•
•
•
|
•
•
•
•
•
•
•
| ||
•
•
•
•
| |||
•
•
•
•
•
•
•
|
•
•
•
•
•
•
|
•
•
•
•
•
•
•
| |
•
•
o
o
o
o
o
o
o
o
o
•
•
Symptoms in males may include: o
o
o
o
o
The most common side effects of desvenlafaxine include: | |||
•
•
•
•
•
|
•
•
•
•
| ||
These are not all the possible side effects of desvenlafaxine. | |||
How should I store desvenlafaxine? •
•
| |||
General Information about the safe and effective use of desvenlafaxine | |||
What are the ingredients in desvenlafaxine? •
•
•
This product's label may have been updated. For current full prescribing information, please visit www.greenstonellc.com. LAB-0781-7.0 | |||
This Medication Guide has been approved by the U.S. Food and Drug Administration. |
Revised: 8/2023 |